v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)
3 Months Ended 6 Months Ended
Jul. 02, 2025
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Jul. 03, 2025
shares
Concentration Risk [Line Items]              
Reverse stock split 1-for-3.33            
Net foreign exchange gains (losses)   $ (22,000) $ 177,000 $ (15,000) $ 171,000    
Number of operating segments | segment       1      
Number of reportable segments | segment       1      
Contract assets   0   $ 0   $ 0  
Costs of revenue   1,772,000 1,504,000 3,235,000 2,793,000    
Advertising costs       0 0    
Research and development   5,309,000 3,392,000 9,744,000 6,499,000    
Impairment of long-lived assets   0 0 0 0    
IPO              
Concentration Risk [Line Items]              
Warrants issued (in shares) | shares             168,898
Private Placement              
Concentration Risk [Line Items]              
Private Placement issuance costs in accounts payable and accruals       600,000      
Shipping and handling              
Concentration Risk [Line Items]              
Costs of revenue   33,000 26,000 68,000 43,000    
Healthcare clinical trial activities              
Concentration Risk [Line Items]              
Research and development   $ 2,371,000 $ 1,054,000 $ 4,005,000 $ 1,751,000